I'm LongbridgeAI, I can summarize articles.Kintor Pharma (9939.HK) climbed more than 6% in Hong Kong trading to HK$1.395.
The stock is down 7.31% over the past ten sessions, down 53.19% over the past six months and down 28.83% year to date.
The Hang Seng Index is up 5.04% over the past five sessions and down 4.53% year to date.
The company announced that it has completed all subject follow-ups in a long-term safety clinical trial for its self-developed KX-826 tincture 1.0% for the treatment of androgenetic alopecia. The multicenter, open-label study was conducted over one year at 12 clinical sites in China, focusing on adverse events and other safety parameters during treatment.
Kintor said the results demonstrated a favorable safety profile, further confirming the long-term safety and efficacy of KX-826. The data will be included alongside positive Phase III results released in March as key materials in a new drug application to be submitted to China's National Medical Products Administration.
Separately, the company received a notification of invention patent grant from the China National Intellectual Property Administration for its self-developed tyrosinase inhibitor KT-939. The patent covers the chemical structure and uses of KT-939, with authorization taking about six months from the priority examination request. Kintor submitted registration materials to the NMPA in September 2026 and is processing subsequent authorization procedures.
Based on public media reports. AI-generated; not investment advice.
